Results 181 to 190 of about 32,074 (246)

Clinical characteristics of Sarcopenic obesity in Japanese people with type 2 diabetes: A post hoc analysis of the sub‐cohort iDIAMOND study

Journal of Diabetes Investigation, EarlyView.
Among participants aged 40–75 years, sarcopenic obesity was observed in 4.9% of those with T2D and 0.5% of non‐D individuals. Sarcopenic obesity is more prevalent in individuals with T2D and is associated with impaired physical QOL, reduced walking ability, and increased falls.
Hiroyasu Mori, Kasei Ko, Satoko Notomi, Sumiko Yoshida, Tetsuyuki Yasuda, Yutaka Umayahara, Sayoko Shimizu, Kayoko Ryomoto, Kazutomi Yoshiuchi, Saeko Osawa, Tsunehiko Yamamoto, Akio Kuroda, Munehide Matsuhisa   +12 more
wiley   +1 more source

Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction To demonstrate noninferiority of continued sodium zirconium cyclosilicate therapy versus a potassium‐restricted diet in achieving normokalemia at Visit 7 (Days 28–42) in individuals with type 2 diabetes and hyperkalemia, using a noninferiority margin of −10 percentage points (one‐sided α = 0.025).
Masahide Hamaguchi, Junya Hironaka, Hiroshi Okada, Mari Yoneda, Ayaka Kobayashi, Yoshitaka Hashimoto, Aya Kitae, Noriyuki Kitagawa, Akio Kishi, Michiyo Ishii, Mai Asano, Masahiro Yamazaki, Toru Tanaka, Hanako Nakajima, Eiko Sato, Michiaki Fukui   +15 more
wiley   +1 more source

Intensified multifactorial intervention leads to long‐term benefit on kidney outcomes in advanced diabetic kidney disease: A 10‐year follow‐up of the DNETT‐Japan trial

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction Despite recent therapeutic advances in slowing kidney disease progression, the long‐term efficacy of intensive multifactorial treatment in advanced‐stage diabetic kidney disease remains unclear. We assessed long‐term kidney outcomes through the 5‐year Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan ...
Kenichi Shikata, Satoshi Miyamoto, Masakazu Haneda, Hiroki Hosoi, Kota Sakamoto, Yoshiki Suzuki, Daisuke Suzuki, Hitoshi Ishida, Hiroaki Akai, Yasuhiko Tomino, Takashi Uzu, Motonobu Nishimura, Hiromi Kuramoto, Michihiro Yoshida, Daisuke Ogawa, Toshiharu Ninomiya, Hirofumi Makino, the Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan) collaborative group   +17 more
wiley   +1 more source

Targeting the miR‐224‐5p/PTEN pathway: A previously under‐characterized strategy to attenuate mesangial cell injury and predict prognosis in diabetic nephropathy

Journal of Diabetes Investigation, EarlyView.
Serum miR‐224‐5p levels are progressively elevated in diabetic nephropathy (DN) and serve as an independent predictor of a decline in eGFR of ≥30% over 2 years. Mechanistically, miR‐224‐5p directly targets PTEN 3’‐UTR, suppressing PTEN and the activation of the AKT pathway in high‐glucose‐stimulated mesangial cells.
Yanxia Gao, Xiaohui Zhang, Peng Lu, Qiang Wang   +3 more
wiley   +1 more source

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

Journal of Diabetes Investigation, EarlyView.
We conducted the single‐center, retrospective cohort study to evaluate and compare the risk of diabetic eye and kidney complications between newly initiated once‐daily liraglutide (0.9 mg) and once‐weekly dulaglutide (0.75 mg) in 331 Japanese patients with type 2 diabetes.
Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami   +4 more
wiley   +1 more source

Angiotensin Receptor Blockers Versus Calcium Channel Blockers for First‐Line Antihypertensive Therapy and Survival in Adults Aged 75 Years or Older

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Evidence guiding first‐line antihypertensive drug choice in adults aged 75 years or older is limited, despite widespread use of angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) in late older age. Methods We conducted a target trial emulation using a new‐user design in a nationwide linked healthcare claims ...
Hisashi Noma, Hiroshi Sunada, Taiki Sugimoto, Ken‐Ei Sada, Futoshi Oda, Megumi Maeda, Haruhisa Fukuda   +6 more
wiley   +1 more source

Neonatal Acute Kidney Injury—An Australian and New Zealand Perspective

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Acute kidney injury (AKI) is increasingly recognized as a critical and underdiagnosed condition among neonates, with significant short and long‐term implications for survival, kidney function, and long‐term cardiovascular health. Neonatal physiology, including ongoing nephrogenesis, immature renal haemodynamics, and limited glomerular ...
Saumil Desai, Thomas Forbes, Simon A. Carter, Alison L. Kent, Chanel Prestidge, David T. Selewski, Eveline Staub, Anke Raaijmakers   +7 more
wiley   +1 more source

Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes

Journal of Periodontal Research, EarlyView.
Key Findings Drug‐target Mendelian randomization showed little evidence that genetically proxied on‐target pharmacological actions of most antihypertensive drug classes were associated with chronic periodontitis or dental caries. The diazoxide–periodontitis association requires cautious interpretation, given possible residual pleiotropy at KCNJ11 and ...
Aiswarya Puzhakkara Chennas, Ignacio Leiva‐Escobar, Stefan Lars Reckelkamm, Birte Holtfreter, Thomas Kocher, Sebastian‐Edgar Baumeister, Michael Nolde, Zoheir Alayash   +7 more
wiley   +1 more source

The Role of the Oral Microbiome in Circulating Metabolic Biomarkers and the Influence of Air Pollution

Oral Diseases, EarlyView.
ABSTRACT Aims The oral microbiome is at the frontline for environmental exposure and plays an important role in human metabolism. This study explores the relationship between PM2.5 exposure, the oral microbiome, and metabolic biomarkers including ghrelin, resistin, and insulin.
Jiajun Luo, Yuqing Wu, Habibul Ahsan, Christopher O. Olopade, Jayant M. Pinto, Briseis Aschebrook‐Kilfoy   +5 more
wiley   +1 more source